Literature DB >> 12068009

Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation.

M Hasan Mohajeri1, Krishan Saini, Jan G Schultz, M Axel Wollmer, Christoph Hock, Roger M Nitsch.   

Abstract

To characterize the effects of the familial Alzheimer's disease-causing Swedish mutations of amyloid precursor protein (SwAPP) on the vulnerability of central nervous system neurons, we induced epileptic seizures in transgenic mice expressing SwAPP. The transgene expression did not change the seizure threshold, but consistently more neurons degenerated in brains of SwAPP mice as compared with wild-type littermates. The degenerating neurons were stained both by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling and by Gallyas silver impregnation. A susceptible population of neurons accumulated intracellular Abeta and immunoreacted with antibodies against activated caspase-3. To demonstrate that increased Abeta levels mediated the increased vulnerability, we infused antibodies against Abeta and found a significant reduction in neuronal loss that was paralleled by decreased brain levels of Abeta. Because the SwAPP mice exhibited no amyloid plaques at the age of these experiments, transgenic overproduction of Abeta in brain rendered neurons susceptible to damage much earlier than the onset of amyloid plaque formation. Our data underscore the possibility that Abeta is toxic, that it increases the vulnerability of neurons to excitotoxic events produced by seizures, and that lowering Abeta by passive immunization can protect neurons from Abeta-related toxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12068009     DOI: 10.1074/jbc.M203193200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Continuous vaccinations of 4Aβ1-15 induces specific fluctuation of inflammatory factors accompany with pathologic alterations alleviation in APP/PS1 mice.

Authors:  Yuwei Zhang; Qingqing Li; Juntao Zou; Zejie Zuo; Zhibin Yao
Journal:  Hum Vaccin Immunother       Date:  2015-08-21       Impact factor: 3.452

2.  Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis.

Authors:  Oliver Wirths; Christian Erck; Henrik Martens; Anja Harmeier; Constanze Geumann; Sadim Jawhar; Sathish Kumar; Gerd Multhaup; Jochen Walter; Martin Ingelsson; Malin Degerman-Gunnarsson; Hannu Kalimo; Inge Huitinga; Lars Lannfelt; Thomas A Bayer
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

3.  Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease.

Authors:  Michael Hanenberg; Jordan McAfoose; Luka Kulic; Tobias Welt; Fabian Wirth; Petra Parizek; Lisa Strobel; Susann Cattepoel; Claudia Späni; Rebecca Derungs; Marcel Maier; Andreas Plückthun; Roger M Nitsch
Journal:  J Biol Chem       Date:  2014-08-12       Impact factor: 5.157

Review 4.  β-Amyloid peptides and amyloid plaques in Alzheimer's disease.

Authors:  Gunnar K Gouras; Tomas T Olsson; Oskar Hansson
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

5.  Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice.

Authors:  Neelima B Chauhan; Francesca Davis; Chun Xiao
Journal:  Vaccine       Date:  2011-08-12       Impact factor: 3.641

6.  The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo.

Authors:  Arames Crameri; Elisa Biondi; Katrin Kuehnle; Dieter Lütjohann; Karin M Thelen; Simona Perga; Carlos G Dotti; Roger M Nitsch; Maria Dolores Ledesma; M Hasan Mohajeri
Journal:  EMBO J       Date:  2006-01-12       Impact factor: 11.598

Review 7.  Bapineuzumab.

Authors:  Geoffrey A Kerchner; Adam L Boxer
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 8.  Active and passive immunotherapy for neurodegenerative disorders.

Authors:  David L Brody; David M Holtzman
Journal:  Annu Rev Neurosci       Date:  2008       Impact factor: 12.449

Review 9.  Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.

Authors:  Roger M Nitsch; Christoph Hock
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 10.  Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Authors:  Gregory A Jicha
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.